Jennifer Brown
Dana-Farber Cancer Institute · University of Basel · Swiss TPH & University of Basel
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jennifer Brown as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:30 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07847957 · Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLDana-Farber Cancer Institute · not yet recruiting · Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT06644183 · Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)Jennifer R. Brown, MD, PhD · recruiting · Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia · principal investigator
- N/ANCT05426421 · Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIVSwiss Tropical & Public Health Institute · completed · HIV · principal investigator
- N/ANCT04028531 · Understanding Chronic Lymphocytic LeukemiaDana-Farber Cancer Institute · recruiting · Chronic Lymphocytic Leukemia · principal investigator
- N/ANCT03969030 · Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in LesothoAmstutz Alain · completed · HIV/AIDS · study director
- Ph3NCT03836261 · Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLAcerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02135133 · A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLDana-Farber Cancer Institute · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph1/Ph2NCT01066663 · Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDana-Farber Cancer Institute · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia · principal investigator
- Ph1NCT00612612 · Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · terminated · B-cell Chronic Lymphocytic Leukemia, Leukemia, Prolymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 22 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INST · fiscal years 2022 to 2026 · $482,183 awarded in 2026Same name and institution; not confirmed by an ID
- Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)R01CA258924 · NCI · DANA-FARBER CANCER INST · fiscal years 2021 to 2025 · $591,132 awarded in 2025Same name and institution; not confirmed by an ID
- Unlocking the Potential of PI3K Inhibition in CLLR01CA213442 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2021 · $571,051 awarded in 2021Grant number is on one of their registry trials
- Biospecimens and Primagraft DevelopmentP01CA206978 · NCI · DANA-FARBER CANCER INST · fiscal years 2016 to 2020 · $316,409 awarded in 2020Same name and institution; not confirmed by an ID
- Genetic Alterations in Families with Multiple LymphomasK23CA115682 · NCI · DANA-FARBER CANCER INST · fiscal years 2005 to 2009 · $69,120 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013Named on NCT00612612
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:30 UTC. The ranking covers the 200 most relevant of 1141 PubMed records, and a shared surname and initials can bring in a namesake. All 1141 on PubMed
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.N Engl J Med · 20141,382 citationsRCR 39.4
- 1,147 citationsRCR 59.9
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.N Engl J Med · 20171,034 citationsRCR 44.5
- Romosozumab in postmenopausal women with low bone mineral density.N Engl J Med · 2014974 citationsRCR 34.3
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med · 2017815 citationsRCR 37.5
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.N Engl J Med · 2018789 citationsRCR 27.0
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.Lancet Diabetes Endocrinol · 2017771 citationsRCR 34.6
- Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock.N Engl J Med · 2018730 citationsRCR 44.5
- Lateral Extra-articular Tenodesis Reduces Failure of Hamstring Tendon Autograft Anterior Cruciate Ligament Reconstruction: 2-Year Outcomes From the STABILITY Study Randomized Clinical Trial.Am J Sports Med · 2020642 citationsRCR 65.3
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.J Bone Miner Res · 2018553 citationsRCR 27.8